Dublin, 31 Dec. 2021 (GLOBE NEWSWIRE) — The “Chinese Leuprorelin Market Survey Report 2021-2025” report has been added to from ResearchAndMarkets.com offer.
According to the market research, the sales value of leuprorelin in the Chinese market increased rapidly year by year from 2016 to 2019.
Due to the impact of the COVID-19 epidemic on the entire diagnostic and treatment services of the hospital, the sales value growth rate decreased from 21.01% in 2019 to 11 .11% in 2020. The sales value of leuprorelin in the Chinese market reached 1108 million yuan in 2020, and the CAGR was 15.1% from 2016 to 2020.
Leuprolide is a synthetic gonadotropin used to treat hormone-sensitive cancers such as prostate cancer and breast cancer. It can also be used to treat precocious puberty and prevent premature ovulation during in vitro fertilization. Leuprolide was patented in 1973 and approved for medical use in the United States in 1985.
In 1992, it obtained the license to import medicine from China. In H1 2021, manufacturers in China leuprolide market are Takeda Pharmaceutical Co., Ltd., Shanghai Livzon Pharmaceutical Co., Ltd. and Beijing Biote Pharmaceutical Co., Ltd.
The analyst expects that with the easing of the COVID-19 outbreak, sales of Leuprorelin will see restorative growth from 2021 to 2025. On August 10, 2020, Shanghai-Takeda China announced that its form A 3-month dose (specification: 11.25 mg) of Innate has been officially approved by China National Medical Products Administration for the treatment of central precocious puberty (CPP).
This is the third indication approved in China for the 3-month dosage form of Innate. Leuprolide sales volume is expected to increase as the number of indications increases, and there is room for sales to increase.
- The impact of COVID-19 on the Chinese leuprorelin market
- Sales value of Chinese leuprorelin 2016-2020
- Competitive Landscape of Chinese Leuprorelin Market
- leuprorelin price in china
- Leuprorelin Price in China by Regions and Manufacturers
- Analysis of factors affecting the development of the Chinese leuprorelin market
- China Leuprorelin Market Outlook 2021 to 2025
Main topics covered:
1 Relevant concepts of leuprorelin
1.1 Indications for leuprorelin
1.2 Leuprorelin Development in China
1.3 Government approval of leuprorelin in China
1.4 The impact of COVID-19 on Leuprorelin Sales in China
2 China Leuprorelin Sales, 2016-2020
2.1 Leuprorelin Sales Value
2.1.1 Overall sales value
2.1.2 Sales Value by Region
2.2 Leuprorelin Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 China Leuprorelin Sales by Dosage Form, 2016-2020
2.3.1 Microspheres for injection
2.3.2 Analysis of other dosage forms
3 Analysis of Leuprorelin Key Manufacturers in China in 2020
3.1 Leuprorelin Key Manufacturers Market Share Analysis
3.1.1 Market Share Survey by Sales Value
3.1.2 Market Share Survey by Sales Volume
3.2 Takeda Pharmaceutical Co., Ltd.
3.2.1 Company profile
3.2.2 China ENANTONE (Leuprorelin by Takeda Pharmaceutical Co., Ltd.) Sales
3.3 Shanghai Livzon Pharmaceutical Co., Ltd.
3.3.1 Company Profile
3.3.2 China Beiyi (Shanghai Livzon Pharmaceutical Co., Ltd. Leuprorelin) Sales
3.4 Beijing Biote Pharmaceutical Co., Ltd.
3.4.1 Company Profile
3.4.2 China Boennuokang (Beijing Biote Pharmaceutical Co., Ltd. Leuprorelin) Sales
4 Leuprorelin Price for Different Manufacturers in China, 2020-2021
4.1 Takeda Pharmaceutical Co., Ltd. (ENANTONE)
4.2 Shanghai Livzon Pharmaceutical Co., Ltd. (Beiyi)
4.3 Beijing Biote Pharmaceutical Co., Ltd. (Boennuokang)
5 China Leuprorelin Market Outlook, 2021-2025
5.1 Influencing Factors of China Leuprorelin Market Development
5.1.1 The impact of COVID-19 on the Chinese leuprorelin market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast
- Takeda Pharmaceutical Co., Ltd.
- Shanghai Livzon Pharmaceutical Co., Ltd.
- Beijing Biote Pharmaceutical Co., Ltd.
For more information on this report, visit https://www.researchandmarkets.com/r/6qrv6h